Asia-Pacific Sees Accelerated Growth in PEGylated Protein Therapeutics Market | CAGR at 6.9%

PEGylation is the process of covalent and non-covalent attachment of polyethylene glycol polymer chains to molecules, such as a drug, therapeutic protein, or vesicle. PEGylated protein therapeutics is estimated to show significant market growth during the forecast period, majorly due to the, growth in demand for PEGylation, rise in number of chronic diseases, and presence of strong pipeline drugs. In addition, PEGylated molecules offer some advantages, such as extended half-life, reduced toxicity, lower immunogenicity, and increase in proteolytic protection, that further support the market growth. The global PEGylated protein therapeutics market was valued at $10,388 million in 2017, and is estimated to reach at $17,813 million by 2025, registering a CAGR of 6.9%

Simply Request Sample Copy of Report:
https://www.alliedmarketresearch.com/request-sample/3726

Market Dynamics:

The PEGylated protein therapeutics market is experiencing rapid growth, driven by increasing demand for biologic drugs across various therapeutic areas, including oncology, autoimmune disorders, and metabolic diseases. The market is characterized by a diverse pipeline of PEGylated biologics targeting multiple disease indications. Key players in the pharmaceutical industry are investing heavily in research and development to advance PEGylation technology and expand their product portfolios. Additionally, strategic collaborations and partnerships between pharmaceutical companies and academic institutions are facilitating the development of novel PEGylated therapeutics.

Therapeutic Applications:

PEGylated protein therapeutics have demonstrated efficacy in treating a wide range of medical conditions. In oncology, PEGylated liposomal formulations of chemotherapy drugs offer improved tumor targeting and reduced systemic toxicity compared to conventional chemotherapy. Similarly, PEGylated interferon-alpha has shown promise in the treatment of viral infections and certain cancers. In autoimmune disorders such as rheumatoid arthritis and multiple sclerosis, PEGylated biologics targeting pro-inflammatory cytokines have emerged as effective disease-modifying therapies. Furthermore, PEGylation has enabled the development of long-acting versions of peptide hormones and growth factors for the treatment of metabolic disorders and hormonal deficiencies.

For Purchase Inquiry of Report:
https://www.alliedmarketresearch.com/purchase-enquiry/3726

Important Key Market Players Are -

• Merck & Co., Inc. (Schering-Plough Corporation),
• UCB S.A.,
• Biogen Inc.,
• Shire plc (Baxalta),
• Horizon Pharma plc.,
• AstraZeneca PLC,
• Amgen Inc.,
• Leadiant Biosciences S.p.A.,
• Pfizer Inc.,
• F. Hoffmann-La Roche Ltd. (Genentech, Inc.,)

PEGylation is a process of addition of active polyethylene glycol (PEG) to different forms of therapeutic proteins for chemical modification. These chemically modified therapeutic proteins are called PEGylated protein therapeutics. The chemical modification due to PEGylation results in various advantages, such as an extended half-life of a drug along with low toxicity and increased proteolytic protection, over the non-modified protein therapeutics. PEGylated protein therapeutics are used in multiple conditions such as cancer, hemophilia, rheumatoid arthritis, ankylosing spondylitis, Crohns disease, and others.

The factors that drive the growth of the global PEGylated protein therapeutics market are increase in prevalence of chronic diseases, advantages offered by PEGylation, and strong presence of pipe line drugs are. However, high cost related to drug development and launch of generics during the forecast period are expected to impede the market growth. In addition, high market potential in the untapped emerging economies and increase in adoption of PEGylated protein therapeutics are expected to provide many opportunities during the forecast period.

Key Findings of The Study -

• North America occupied nearly two-thirds share of the global PEGylated protein therapeutics market in 2017
• The cancer segment is anticipated to grow with the highest CAGR throughout the forecast period.
• Europe is anticipated to occupy one-fifth market share of the global PEGylated protein therapeutics market by 2025.
• Asia-Pacific is anticipated to grow at the highest rate during the analysis period, followed by LAMEA.

Simply Speak To Expert For More Clarification:
https://www.alliedmarketresearch.com/connect-to-analyst/3726

Geographic Segments Covered in the Report -

The PEGylated Protein Therapeutics Market report provides information about the market area, which is further subdivided into sub-regions and countries/regions. In addition to the market share in each country and sub-region, this chapter of this report also contains information on profit opportunities. This chapter of the report mentions the market share and growth rate of each region, country, and sub-region during the estimated period.

• North America (USA and Canada)

• Europe (UK, Germany, France and the rest of Europe)

• Asia Pacific (China, Japan, India, and the rest of the Asia Pacific region)

• Latin America (Brazil, Mexico, and the rest of Latin America)

• Middle East and Africa (GCC and rest of the Middle East and Africa)

Frequently Asked Questions?

Q1. What are the Key Industry Leaders opinion for the Global PEGylated Protein Therapeutics Market?

Q2. Which market holds the maximum market share of the Global PEGylated Protein Therapeutics Market?

Q3. What is the total market value of Global PEGylated Protein Therapeutics Market report?

Q4. What would be forecast period in the market report?

Q5. What is the market value of Global PEGylated Protein Therapeutics Market in 2020?

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com

About Us -

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

Pawan Kumar, the CEO of Allied Market Research is leading the organization toward providing high-quality data and insights. We are in professional corporate relations with various research data tables and confirms utmost accuracy in our market forecasting. Each and every us companies and this helps us in digging out market data that helps us generate accurate y data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

This release was published on openPR.